Date: 2014-11-27
Type of information: Opening of new premises
Compound: new packaging facility at the Hatfield production plant
Company: Eisai (Japan)
Therapeutic area: CNS diseases - Neurological diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On November 27, 2014, Eisai announced that construction of a new packaging facility has been completed at its Hatfield, Hertfordshire production plant in the United Kingdom ahead of plans to launch multiple new Eisai products. The Hatfield plant is operated by the company\'s U.K. manufacturing subsidiary, Eisai Manufacturing Ltd. The Hatfield plant serves as a global supply center for new products such as antiepileptic agent Fycompa® while also functioning as a production and packaging base for countries in Europe, where there is a demand for a high mix of low-volume product presentations in multiple languages. Located adjacent to the currently operating facility, the New Facility covers a total floor space of approximately 2,900 m2, representing an increase in size of approximately 40%. Housing a packaging line with cutting-edge technology, the New Facility is specifically designed to cope with highly potent compounds to handle the packaging of Eisai\'s investigational anticancer agent lenvatinib, and Eisai intends for the Hatfield plant to serve as the global supply center for lenvatinib.
- Eisai established the European Knowledge Centre (EKC), which integrates the company\'s discovery research, clinical development, production, marketing, and European headquarters functions into one site, in Hatfield, Hertfordshire in 2009 with the aim of expanding its business operations in Europe. At present, the EKC plays an even more important role as the regional headquarters for Eisai\'s EMEA business which covers Europe, the Middle East, Africa and Oceania.
Financial terms:
Latest news:
Is general: Yes
